YPH Stock Overview
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.60 |
| 52 Week High | JP¥15.61 |
| 52 Week Low | JP¥8.53 |
| Beta | 0.28 |
| 1 Month Change | -13.98% |
| 3 Month Change | -16.08% |
| 1 Year Change | -34.83% |
| 3 Year Change | -28.58% |
| 5 Year Change | -27.90% |
| Change since IPO | 41.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| YPH | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.6% | 3.2% | 1.7% |
| 1Y | -34.8% | -28.2% | 2.3% |
Return vs Industry: YPH underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: YPH underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| YPH volatility | |
|---|---|
| YPH Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YPH's share price has been volatile over the past 3 months.
Volatility Over Time: YPH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 14,484 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| YPH fundamental statistics | |
|---|---|
| Market cap | €15.81b |
| Earnings (TTM) | €25.19m |
| Revenue (TTM) | €9.26b |
621.4x
P/E Ratio1.7x
P/S RatioIs YPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YPH income statement (TTM) | |
|---|---|
| Revenue | JP¥1.54t |
| Cost of Revenue | JP¥281.54b |
| Gross Profit | JP¥1.26t |
| Other Expenses | JP¥1.26t |
| Earnings | JP¥4.20b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 2.34 |
| Gross Margin | 81.76% |
| Net Profit Margin | 0.27% |
| Debt/Equity Ratio | 58.1% |
How did YPH perform over the long term?
See historical performance and comparison